Lung Cancer Therapeutics Market Key Companies, Business Opportunities, Competitive Landscape and Industry Analysis Research Report by 2032

The global lung cancer therapeutics market size was USD 28.00 Billion in 2022 and is expected to register a rapid revenue CAGR of 7.7% during the forecast period. The global lung cancer therapeutics market is experiencing rapid growth, driven by an increased demand for innovative treatments aimed at addressing the rising incidence of lung cancer. This trend is largely fueled by persistent tobacco use in certain regions and the growing need for targeted therapies, which offer a more effective and less invasive treatment option compared to traditional chemotherapy. The market is expected to continue expanding as advancements in precision medicine and healthcare services become more widely available.

Get Free Sample Report and Related Graphs & Charts @ https://www.emergenresearch.com/request-sample/2636

Key Drivers of Market Growth

Lung cancer remains one of the leading causes of cancer-related deaths worldwide. The high prevalence of tobacco use, particularly in some countries, continues to be a major contributor to the increasing number of lung cancer cases. As a result, there is a growing need for effective therapeutic solutions to manage and treat this disease. Targeted therapies, which focus on specific genetic mutations in cancer cells, have emerged as a breakthrough in lung cancer treatment, offering improved outcomes with fewer side effects.

Targeted therapies work by identifying and attacking cancer cells based on their genetic makeup, sparing healthy cells and reducing the debilitating side effects often associated with chemotherapy. Patients receiving targeted therapies report a higher quality of life during treatment, making these therapies an attractive option for those seeking less invasive and more effective cancer care.

Challenges Facing the Market

Despite the advancements in treatment options, challenges remain in lung cancer therapeutics. Side effects from existing treatments, such as nausea, fatigue, and hair loss, continue to impact patient well-being and treatment adherence. These side effects can discourage patients from continuing their treatment, reducing its overall effectiveness. Additionally, the need for ongoing monitoring and supportive care for patients places a strain on healthcare resources.

Emerging Trends and Innovations

A significant trend in lung cancer treatment is the development of therapies tailored to the genetic mutations specific to certain types of lung cancer. For instance, mutations in the Epidermal Growth Factor Receptor (EGFR) and rearrangements in the Anaplastic Lymphoma Kinase (ALK) gene are common in Non-Small Cell Lung Cancer (NSCLC). Targeted drugs such as afatinib, osimertinib, and lorlatinib have shown promising results in improving treatment outcomes for patients with these mutations.

This shift toward personalized medicine marks a new era in cancer treatment, offering patients more effective, individualized care based on their genetic profiles. The ability to treat lung cancer at the molecular level with greater precision is expected to further drive demand for targeted therapies.

Market Segmentation Insights

The global lung cancer therapeutics market is segmented by therapy type, with targeted therapy leading the market due to its specificity and improved patient outcomes. Targeted therapies, which focus on the unique genetic characteristics of tumors, accounted for the largest market share in 2022 and are expected to continue dominating the market.

Chemotherapy, while effective in treating both small cell and non-small cell lung cancers, is projected to grow at a more moderate rate due to its broader application across various cancer stages. Chemotherapy remains a primary treatment option, particularly for advanced or metastatic lung cancer cases, where it helps to alleviate symptoms and improve quality of life.

Get a Discount On The Purchase Of This Report @ https://www.emergenresearch.com/request-discount/2636

Distribution Channel Dynamics

Hospitals currently represent the largest distribution channel for lung cancer therapeutics, as they provide comprehensive cancer care, including the administration of both chemotherapy and targeted therapies. Hospitals are equipped with healthcare professionals who can closely monitor patients and manage side effects, making them the preferred choice for cancer treatment, especially for patients with complex medical needs.

Lung Cancer Therapeutics Top Companies and Competitive Landscape

The global lung cancer therapeutics market is moderately fragmented, with many large and medium-sized players accounting for majority of market revenue. Major businesses are using a variety of tactics, making mergers and acquisitions, strategic agreements, and contracts, as well as creating, experimenting with, and introducing more efficient lung cancer therapeutics solutions in the market.

Some major players included in the global lung cancer therapeutics market report are:

GlaxoSmithKline plc.

Pfizer Inc.

Sun Pharmaceutical Industries Ltd.

Takeda Pharmaceutical Company Limited

ONO PHARMACEUTICAL CO., LTD.

Hoffmann-La Roche Ltd

Novartis AG, Lily.

AstraZeneca

Boehringer Ingelheim International GmbH

Merck & Co., Inc.

CELGENE CORPORATION

Sanofi

Johnson & Johnson Services, Inc.

Reddy's Laboratories Ltd.

ALLERGAN

Teva Pharmaceutical Industries Ltd.

Bristol-Myers Squibb Company (US)

Millennium Pharmaceuticals, Inc.

Celgene Corporation

Lung Cancer Therapeutics Latest Industry Updates

On 10 July, 2023, Iovance Biotherapeutics announced positive regulatory and clinical updates regarding its Phase 2 IOV-LUN-202 trial for LN-145 TIL therapy in post-anti-PD-1 advanced NSCLC. During discussions with the U.S. FDA, the agency expressed positive feedback on the trial design, indicating it may be suitable for accelerated approval. Preliminary clinical data from the IOV-LUN-202 trial showed a 26.1% Objective Response Rate (ORR) in post-anti-PD-1 NSCLC patients. Iovance plans to enroll around 120 patients in the trial, with expected completion in the second half of 2024. The company is also preparing for discussions with the FDA on a randomized confirmatory trial for LN-145 in frontline advanced NSCLC.

On 27 July, 2020, AstraZeneca announced a global collaboration with Daiichi Sankyo to develop and commercialize DS-1062, an Antibody Drug Conjugate (ADC) designed to target the trophoblast cell-surface antigen 2 (TROP2). DS-1062, under development for multiple cancer types, including NSCLC and breast cancer, leverages Daiichi Sankyo's proprietary ADC technology to selectively deliver chemotherapy to cancer cells. AstraZeneca paid USD1 billion to Daiichi Sankyo as an upfront payment, with the potential for additional conditional payments of up to USD 5 billion based on regulatory approvals and sales milestones.

Purchase This Market Research Report - https://www.emergenresearch.com/select-license/2636

For the purpose of this report, Emergen Research has segmented the global Lung cancer therapeutics market on the basis of type, application, deployment, enterprise size, component, vertical, and region:

Therapy Outlook (Revenue, USD Billion; 2019-2032)

Targeted Therapy

Bevacizumab

Dabrafenib/Trametinib

Erlotinib Hydrochloride

Osimertinib

Others

Immunotherapy

Durvalumab

Nivolumab

Atezolizumab

Pembrolizumab

Chemotherapy

Cisplatin

Taxol

Navelbine

Camptosar

Alimta

Distribution Outlook (Revenue, USD Billion; 2019-2032)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Cancer Outlook (Revenue, USD Billion; 2019-2032)

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Molecule Outlook (Revenue, USD Billion; 2019-2032)

Biologics

Small Molecules

Mode of Administration Outlook (Revenue, USD Billion; 2019-2032)

Injectable

Oral

Type Outlook (Revenue, USD Billion; 2019-2032)

Acute Myeloid Leukemia (AML)

Chronic Myeloid Leukemia (CML)

Acute Lymphoblastic Leukemia (ALL)

Chronic Lymphocytic Leukemia (CLL)

End-use Outlook (Revenue, USD Billion; 2019-2032)

Hospitals

Research Institutes

Regional Outlook (Revenue, USD Billion; 2019-2032)

North America

U.S.

Canada

Mexico

Europe

Germany

France

UK

Italy

Spain

Benelux

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Rest of APAC

Latin America

Brazil

Rest of LATAM

Middle East & Africa

Saudi Arabia

UAE

South Africa

Turkey

Rest of Middle East & Africa

For more informative information, please visit us @ https://www.emergenresearch.com/industry-report/lung-cancer-therapeutics-market

Look Over transcripts provided by Emergen Research

Lung Cancer Therapeutics Market Size@ https://www.emergenresearch.com/industry-report/lung-cancer-therapeutics-market/market-size

Lung Cancer Therapeutics Market Share@ https://www.emergenresearch.com/industry-report/lung-cancer-therapeutics-market/market-share

Lung Cancer Therapeutics Market Trends@ https://www.emergenresearch.com/industry-report/lung-cancer-therapeutics-market/market-trends

Lung Cancer Therapeutics Regional Market Demand@ https://www.emergenresearch.com/industry-report/lung-cancer-therapeutics-market/regional-market-demand

Lung Cancer Therapeutics Market Analysis@ https://www.emergenresearch.com/industry-report/lung-cancer-therapeutics-market/market-analysis

Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Visit for More Insights: https://www.emergenresearch.com/insights

About Us:
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

This release was published on openPR.